Organization | Pharma Medica

Pharma Medica Report issue

For profit Phase 1 Phase 2

Founded: Mississauga ON United States (1998)

Status: Defunct (2019)

Organization Overview

First Clinical Trial

1998

NCT00883155

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Pharma Medica Research | Pharma Medica Research, Inc. | Pharma Medica Research Inc. Canada

Active Ingredients

Drugs in Phase 2 Trials (1)

icosapent ethyl (vascepa) (1 trial)

Drugs in Phase 1 Trials (20)

anastrozole (arimidex) (2 trials)

bupropion (wellbutrin) (1 trial)

cetirizine (zyrtec) (2 trials)

clavulanate (Augmentin) (2 trials)

diethylcarbamazine (hetrazan) (1 trial)

granisetron (kytril) (2 trials)

ibuprofen (motrin) (1 trial)

leflunomide (arava) (1 trial)

mycophenolate (myfortic) (2 trials)

naloxone (narcan) (1 trial)

oxcarbazepine (trileptal) (1 trial)

pravastatin (pravachol) (3 trials)

procaine benzylpenicillin (novocaine) (2 trials)

pseudoephedrine (Benylin) (3 trials)

s1226 (1 trial)

sodium chloride (1 trial)

tamsulosin (flomax) (2 trials)

trandolapril (mavik) (1 trial)

ursodeoxycholic acid (2 trials)

valproic acid (depakene) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Pain (Phase 1)

Back Pain (Phase 1)

Bipolar Disorder (Phase 1)

Disease (Phase 1)

Epilepsy (Phase 1)

Headache (Phase 1)

Hypertriglyceridemia (Phase 2)

Malnutrition (Phase 1)

Seizures (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 28
# of Trial APIs: 21